Lawsuits Filed in the Wake of Bayer’s Withdrawal of Trasylol From the Market
FOR IMMEDIATE RELEASE
New York, New York, November 6, 2007: In the wake of Bayer’s announcement yesterday that it was pulling its controversial heart surgery drug Trasylol from the market after a Canadian study suggested that its use increased surgical complications and death rates, nationally known plaintiff’s advocates Napoli Bern & Associates, LLP has filed a second litigation seeking damages for a heart patient’s death.
The lawsuit, Harriet N. Cohen, A/K/A Harriet N. Feinberg, Executrix Of The Estate Of Arthur Feinberg, A/K/A Arthur W. Feinberg, And Harriet N. Cohen, Individually v. Bayer Corporation, et al., was filed in the Superior Court of Connecticut, District of New Haven. The patient, Arthur W. Feinberg, M.D., was a retired internist and geriatrician, a founding member of North Shore University Hospital in New York and a former professor of clinical medicine at Cornell University and New York University. Dr. Feinberg died on November 28, 2005, shortly after undergoing heart surgery during which his surgeon ordered the use of Trasylol, a drug used to minimize intraoperative bleeding. As a result of the use of Trasylol, Dr. Feinberg suffered severe renal failure and severe cardiovascular injuries soon after heart surgery, which ultimately led to his death. Another case has also been filed by Napoli Bern & Associates, LLP, arising from horrific post-surgical complications suffered by Joseph Randone, a 52 year old man who suffered kidney failure leading to a chain reaction resulting in his death following routine valve replacement surgery where Trasylol was utilized (Josephine Randone, Executrix Of The Estate Of Joseph Randone, And Josephine Randone, Individually, v. Bayer Corporation, et al.).
Two weeks ago, the Ottawa Health Research Institute stopped their study of Trasylol in 3,000 heart bypass and valve surgery patients, upon their finding that while those given the drug suffered less intraoperative bleeding, they had a 50% higher chance of dying post surgically than those patients who were given one or another of two older medical alternatives. Dr. John K. Jenkins, an official of the Food and Drug Administration, said the “F.D.A. could not identify a specific patient population where the benefits of using Trasylol could outweigh the risks.” FDA said that the fact that the Ottawa group ended their study early was a strong factor in their decision to request that Bayer withdraw the drug from the market.
About the Firm:
Napoli Bern & Associates, LLP, a nationally-known law firm advocating on behalf of injured plaintiffs in pharmaceutical and environmental tort matters, is based in Manhattan and Great River, New York, and has offices in Philadelphia, New Jersey, and Oklahoma. The firm has successfully litigated claims of thousands of persons injured by the diet drugs Fenfluramine and dexfenfluramine (ReduxTM), Rezulin, Propulsid and represents clients in environmental claims arising from petroleum spills and MTBE contamination throughout the eastern United States, as well as over ten thousand plaintiffs suffering toxic exposure injuries after working on the debris pile at the site of the World Trade Center following the September 11, 2001 attacks.
- Contact Information
- Paul J. Napoli
- Senior Partner
- Napoli Bern & Associates, LLP
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.